Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Over the weekend the Nikkei reported that Nippon Life would bid ¥60bn for <a href="https://www.smartkarma.com/entities/medical-data-vision-co-ltd" target="_blank" data-smartkarma-citation="entities:8367:1" rel="noopener">Medical Data Vision (3902 JP)</a>. At one price per share, that meant ¥1,585.  </li>
<li>There is a deemed dividend treatment buyback for SBI at ¥1,189 which means they will end up with a capital loss (their in-price is ¥1,630) but they'll offset that.</li>
<li>This is the biggest win for minorities in a long while. Be happy.</li>
</ul>


Over the weekend the Nikkei reported that Nippon Life would bid ¥60bn for Medical Data Vision (3902 JP). At one price per share, that meant ¥1,585.  
There is a deemed dividend treatment buyback for SBI at ¥1,189 which means they will end up with a capital loss (their in-price is ¥1,630) but they'll offset that.
This is the biggest win for minorities in a long while. Be happy.


[Japan M&A] Nippon Life Shoots the Lights Out with a Bid at ¥1,693

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medical-data-vision-co-ltd" target="_blank" data-smartkarma-citation="entities:8367:1" rel="noopener">Medical Data Vision (3902 JP)</a> has recommended a tender offer from Nippon Life at JPY1,693, a 212.4% premium to the last close.</li>
<li>The substantial takeover premium reflects the outcome of an auction and <a href="https://www.smartkarma.com/entities/sbi-holdings-inc" target="_blank" data-smartkarma-citation="entities:10928:1" rel="noopener">SBI Holdings (8473 JP)</a> willingness to share TOB tax benefits with minority shareholders. </li>
<li>The substantial takeover premium also ensures that this is a done deal. The tender closes on 3 February, with payment commencing from 9 February. </li>
</ul>



Medical Data Vision (3902 JP) has recommended a tender offer from Nippon Life at JPY1,693, a 212.4% premium to the last close.
The substantial takeover premium reflects the outcome of an auction and SBI Holdings (8473 JP) willingness to share TOB tax benefits with minority shareholders. 
The substantial takeover premium also ensures that this is a done deal. The tender closes on 3 February, with payment commencing from 9 February. 


Medical Data Vision (3902 JP): Nippon Life’s Tender Offer at JPY1,693 (3x Last Close)

<ul>
<li>The <a href="https://asia.nikkei.com/business/business-deals/nippon-life-seeks-to-buy-medical-data-firm-in-m-a-milestone" target="_blank" rel="noopener">Nikkei reports</a> that Nippon Life Insurance will launch a tender offer for <a href="https://www.smartkarma.com/entities/medical-data-vision-co-ltd" target="_blank" data-smartkarma-citation="entities:8367:1" rel="noopener">Medical Data Vision (3902 JP)</a> at a valuation up to JPY60 billion.</li>
<li>If the valuation refers to market cap, the offer is JPY1,500, a 225% premium to the last close of JPY462. If it relates to EV, the offer price is JPY1,550. </li>
<li>Despite the staggering premium, it does not represent an all-time high (share price traded higher in November 2021). Nevertheless, a binding proposal would be a done deal. </li>
</ul>


The Nikkei reports that Nippon Life Insurance will launch a tender offer for Medical Data Vision (3902 JP) at a valuation up to JPY60 billion.
If the valuation refers to market cap, the offer is JPY1,500, a 225% premium to the last close of JPY462. If it relates to EV, the offer price is JPY1,550. 
Despite the staggering premium, it does not represent an all-time high (share price traded higher in November 2021). Nevertheless, a binding proposal would be a done deal. 


Medical Data Vision (3902 JP): Nippon Life’s Rumoured Tender Offer at 3x the Last Close

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medical-data-vision-co-ltd" target="_blank" data-smartkarma-citation="entities:8367:1" rel="noopener">Medical Data Vision (3902 JP)</a> was IPOed in 2014. MitCorp sold. Others sold. Fujifilm and Medipal stayed in. The stock ran up. SBI bought from Fujifilm in Nov2020 at ¥2355.</li>
<li>The stock fell, SBI bought more in 2021-2022. Then it fell more in 2023 and SBI bought more, then fell more in 2024 and SBI bought more. </li>
<li>The Nikkei <a href="https://www.nikkei.com/article/DGXZQOUB115D70R10C25A9000000/" target="_blank" rel="noopener">reports</a> today that Nippon Life will announce a TOB on 15 December with a max price of ¥60bn (242% premium), which coincidentally would bring SBI close to breakeven.</li>
</ul>



Medical Data Vision (3902 JP) was IPOed in 2014. MitCorp sold. Others sold. Fujifilm and Medipal stayed in. The stock ran up. SBI bought from Fujifilm in Nov2020 at ¥2355.
The stock fell, SBI bought more in 2021-2022. Then it fell more in 2023 and SBI bought more, then fell more in 2024 and SBI bought more. 
The Nikkei reports today that Nippon Life will announce a TOB on 15 December with a max price of ¥60bn (242% premium), which coincidentally would bring SBI close to breakeven.


[Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn

Nippon Investment Bespoke Research UK Ltd

Nippon Investment Bespoke Research UK

Equity Bottom-Up

<ul><li>Medical Data Vision’s [MDV] produced FY25 (Dec year-end) Q3 gross profit [GP] of ¥3,248mil (+6.3% YoY) and operating profit [OP]of ¥95mil (vs FY24 Q3’s operating loss of -¥140mil) on sales of ¥4,650mil (+12.7% YoY).</li><li>FY25 is the last year of the ongoing 3-year medium-term management plan [MTP].</li><li>MDV revised down the FY25 guidance on 14 October from OP of ¥2,600mil (vs a recovery from ¥3mil in FY24) on sales of ¥9,000mil (+52.4% YoY) to OP of ¥490mil on sales of ¥6,860mil (+16.1% YoY).</li></ul>

Medical Data Vision’s [MDV] produced FY25 (Dec year-end) Q3 gross profit [GP] of ¥3,248mil (+6.3% YoY) and operating profit [OP]of ¥95mil (vs FY24 Q3’s operating loss of -¥140mil) on sales of ¥4,650mil (+12.7% YoY).FY25 is the last year of the ongoing 3-year medium-term management plan [MTP].MDV revised down the FY25 guidance on 14 October from OP of ¥2,600mil (vs a recovery from ¥3mil in FY24) on sales of ¥9,000mil (+52.4% YoY) to OP of ¥490mil on sales of ¥6,860mil (+16.1% YoY).

Medical Data Vision Co., Ltd (3902 JP): RESEARCH UPDATE

Japan

Medical Data Vision Co.,Ltd. was founded in 2003. The company's line of business includes developing integrated medical information systems, analysis of medical information, and business consulting for medical institutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medical Data Vision (3902 JP)

[Japan M&A] Nippon Life Shoots the Lights Out with a Bid at ¥1,693

SBI bought high early, then added more on successive steps down, buying their last 5% at 75-80% below their firs 20%. That left their average price...

Travis Lundy